Hui Liu

Hui Liu has an extensive work background in the field of medical research and science. Their experience spans multiple roles and positions, beginning with their time as a Graduate Student at both MIT and the Koch Institute for Integrative Cancer Research at MIT from 2002 to 2009. Following this, they worked as a Postdoctoral Researcher at the Beth Israel Deaconess Medical Center from 2010 to 2016, where they conducted research on triple negative breast cancer and lung cancer, leading to the development and licensing of a targeted therapy. They then served as an Instructor of Medicine at the same institution from 2017 to 2020, where they led multi-lab projects and investigated disease mechanisms in triple negative breast cancer. After this, Hui Liu transitioned to working in the industry, first as a Senior Scientist at Exo Therapeutics from 2020 to 2021, and then as a Principal Scientist from 2022 until their current role. They are currently working as an Associate Principal Scientist at AstraZeneca, where they continue their research and contribute to the development of innovative solutions in their field.

Hui Liu has a Ph.D. in Biology/Cancer metastasis from the Massachusetts Institute of Technology, which was obtained between the years 2002 and 2009. Prior to that, Hui Liu completed a Master of Science degree in Immunology at the University of Georgia from 1998 to 2001.